Literature DB >> 17728193

Experience using centralized spirometry in the phase 2 randomized, placebo-controlled, double-blind trial of denufosol in patients with mild to moderate cystic fibrosis.

C H Goss1, E F McKone, D Mathews, D Kerr, J S Wanger, S P Millard.   

Abstract

BACKGROUND: Centralized spirometry may significantly improve quality of spirometry and reduce variability of this outcome measure in clinical trials in cystic fibrosis (CF).
METHODS: Spirometry was performed during the phase 2 randomized, placebo-controlled, double-blind clinical trial of denufosol in patients with mild to moderate CF using American Thoracic Society guidelines. Uniform spirometers were used with electronic data transmission of all the data to a reading center. Spirometry was evaluated for quality by a central reader based on start of test, cough during the test, and evidence of a plateau.
RESULTS: A total of 1418 spirometry values were assessed in 89 subjects during the trial. In only 5 instances did the central reading center need to give feedback to sites regarding the quality of spirometry. The study site data matched the central reading center's data for all but 78 (6%) spirometry values in 33 patients. Many of these differences were small with only 35 (3%) values differing by more than 50 mL in 26 patients.
CONCLUSION: Spirometry in this clinical trial was of high quality with low rate of significant centralized over-read.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17728193     DOI: 10.1016/j.jcf.2007.07.006

Source DB:  PubMed          Journal:  J Cyst Fibros        ISSN: 1569-1993            Impact factor:   5.482


  4 in total

Review 1.  Advancing outcome measures for the new era of drug development in cystic fibrosis.

Authors:  Nicole Mayer-Hamblett; Bonnie W Ramsey; Richard A Kronmal
Journal:  Proc Am Thorac Soc       Date:  2007-08-01

2.  Rationale and design of a randomized trial of home electronic symptom and lung function monitoring to detect cystic fibrosis pulmonary exacerbations: the early intervention in cystic fibrosis exacerbation (eICE) trial.

Authors:  N Lechtzin; N West; S Allgood; E Wilhelm; U Khan; N Mayer-Hamblett; M L Aitken; B W Ramsey; M P Boyle; P J Mogayzel; C H Goss
Journal:  Contemp Clin Trials       Date:  2013-09-19       Impact factor: 2.226

Review 3.  Role of the Purinergic P2Y2 Receptor in Pulmonary Hypertension.

Authors:  Mazen Shihan; Tatyana Novoyatleva; Thilo Lehmeyer; Akylbek Sydykov; Ralph T Schermuly
Journal:  Int J Environ Res Public Health       Date:  2021-10-20       Impact factor: 3.390

Review 4.  TMEM16A/ANO1: Current Strategies and Novel Drug Approaches for Cystic Fibrosis.

Authors:  Christie Mitri; Himanshu Sharma; Harriet Corvol; Olivier Tabary
Journal:  Cells       Date:  2021-10-24       Impact factor: 6.600

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.